For laboratory research use only. Not for human or veterinary use.
Tirzepatide vial, Prime Core Dynamics

Tirzepatide

Dual GIP and GLP-1 receptor agonist, 39-residue backbone

Incretin receptor agonists Research use only
  • Catalog no. TIRZ-30MG-A01
  • Format Lyophilized powder
Buy on primecoredynamics.com View certificate
Size 10 mg selected
Buy on primecoredynamics.com

Purchase requires a research-use acknowledgement at checkout. Prices as listed on primecoredynamics.com; ordering completes there.

Identity and specifications

Identity

Name
Tirzepatide
CAS number
2023788-19-2
Molecular formula
C225H348N48O68
Molecular weight
4813.50
Appearance
White
Storage
Refrigerated at 36 to 46°F (2 to 8°C); frozen at minus 4°F (minus 20°C) or below for long-term storage. Keep away from light, moisture and heat.
About this material

Molecule class and status

Tirzepatide is a synthetic 39-residue peptide developed under the code LY3298176. It is characterized as a dual agonist at the GIP receptor and the GLP-1 receptor. The same molecule is the active ingredient in prescription medicines approved by the FDA; the material supplied here is not a pharmaceutical product, is not made or distributed under a drug license, and is intended only for laboratory research. It is supplied as a lyophilized powder, identified by lot with a third-party certificate of analysis.

Analytical data

Latest lot

TIRZ-30MG-A01
Lot
>99.9%
HPLC purity
Sep 10, 2026
Test date
Krause Analytical
Laboratory

HPLC-UV/MS purity, mass spectral identity. Values as published on the lot certificate.

View certificate
Handling and storage

Chemical properties

  • Physical form: lyophilized powder in a sealed vial.
  • The sealed vial is stable at room temperature during transit and can be held in a cool, dry, dark place for short periods.
  • Beyond short-term holding, store refrigerated at 36 to 46°F (2 to 8°C), or frozen at minus 4°F (minus 20°C) or below for long-term storage.
  • Keep away from light, moisture and heat.
  • Lyophilized material is stable for the period stated on the certificate for the lot.
Research literature

Citations

Citations are provided for reference. Prime Core Dynamics makes no claim based on them.

  1. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 2018. doi:10.1016/j.molmet.2018.09.009
Regulatory status

Status

Tirzepatide is the active ingredient in FDA-approved prescription medicines. The material sold here is not one of those medicines, is not manufactured under a drug approval, and is not a substitute for any prescription product. It is not a drug, supplement, food or cosmetic and has not been evaluated by the FDA. Sold for laboratory research only.

Statement reviewed against the product's regulatory standing as of Sept 2026.

For laboratory research use only. Not for human or veterinary use. Not a drug, supplement, food or cosmetic. Not evaluated by the FDA.

Documents

Documents